small molecule

BEQALZI

SONROTOCLAX

Loss of exclusivityApril 2039latest FDA-listed patent expiry

CompanyBEONE MEDICINES USA INC

Drug detail

Brand name	BEQALZI
Active ingredient	SONROTOCLAX
Strength	80MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
11420968	April 2039	substance, product

Regulatory exclusivity

Code	Expires
NCE	May 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BEONE MEDICINES USA INC